Abstract: An optically pumped magnetometer includes cells configured to form a first cell region and a second cell region on a measurement target, a pump laser, a probe laser, a first optical system configured to cause pump light to be incident on the first cell region, a second optical system configured to cause the pump light having passed through the first cell region to be incident on the second cell region, a third optical system configured to cause first probe light to be incident on the first cell region, a fourth optical system configured to cause second probe light to be incident on the second cell region, detection portions configured to detect the first probe light having passed through the first cell region and the second probe light having passed through the second cell region, and a deriving portion configured to derive an intensity of a magnetic field.

Abstract: Provided in one aspect is a pharmaceutical composition for analgesia. The present disclosure relates to a pharmaceutical composition for analgesia that contains an a2 adrenergic receptor antagonist as an active ingredient. In one or more embodiments, the pharmaceutical composition according to the present disclosure is a composition for analgesia through inhibition of an a2 adrenergic receptor, or a composition for analgesia through inhibition of an a2B adrenergic receptor.

Abstract: A proton conductor is in contact with a catalyst containing platinum. The proton conductor includes a cationic organic molecule, a metal ion, and an oxoacid anion. A protic ionic liquid containing the cationic organic molecule and the oxoacid anion is coordinated to the metal ion to form a coordination polymer.

Abstract: The present disclosure provides a method for treating an inflammatory condition, especially an age related inflammatory condition in a mammalian subject in need thereof, which comprises an effective amount of a virus like particle comprising a viral structural protein and a galectin-3 antigen, a composition or vaccine comprising for the purpose thereof.

Abstract: A semiconductor device includes a p-type nitride semiconductor layer, the p-type nitride semiconductor layer including an Al-containing nitride semiconductor layer and an Al-containing compound layer containing Al and C as main constituent elements and provided on the surface of the Al-containing nitride semiconductor layer.

Abstract: According to one embodiment, a structure evaluation system includes a plurality of sensors, an acquirer, a calculator, and an evaluator. The plurality of sensors detects elastic waves generated from the structure. The acquirer acquires detection information for an evaluation target period in which information on at least an amplitude of each elastic wave detected by each of the plurality of sensors is associated with time information on the time when each elastic wave is detected. The calculator calculates an evaluation value, which is a slope of an amplitude scale-based frequency distribution of elastic waves, every predetermined period based on the acquired detection information for the evaluation target period. The evaluator evaluates a deterioration state of the structure based on the time-series data of each evaluation value calculated every predetermined period.

Abstract: A method for manufacturing a GaN-based surface-emitting laser by an MOVPE includes: growing a first cladding layer with a {0001} growth plane; growing a guide layer on the first cladding layer; forming holes which are two-dimensionally periodically arranged within the guide layer; etching the guide layer by ICP-RIE using a chlorine-based gas and an argon; supplying a gas containing a nitrogen to cause mass-transport, and then supplying the group-III gas for growth, whereby a first embedding layer closing openings of the holes is formed to form a photonic crystal layer; and growing an active layer and a second cladding layer on the first embedding layer, The step includes a step of referring to already-obtained data on a relationship of an attraction voltage and a ratio of gases in the ICP-RIE with a diameter distribution of air holes embedded, and applying the attraction voltage and the ratio to the ICP-RIE.

Abstract: A method for acquiring and producing high-purity renal progenitor cells from a renal progenitor cell population into which pluripotent stem cells are induced to differentiate, by identifying a cell surface antigen marker specific to renal progenitor cells. The high-purity renal progenitor cells can be used in regenerative medicine for renal diseases, such as renal failure.

Abstract: The present invention relates to a low-molecular antibody composed of D-amino acids and achiral glycine, a method for producing the same, and a method for screening the low-molecular antibody using a mirror-image target protein corresponding to a target protein and an antibody library.

Abstract: A cell evaluation method evaluates the quality of a cell population including a plurality of cells. The cell evaluation method comprises: an index calculation step of calculating an index, based on a captured image of the cell population, the index including at least any one of an average distance representing a packing degree of the cells, a spring constant representing a degree of consistency in distances between the cells, and a hexagonal order parameter representing a degree to which an arrangement of the cells resembles a regular hexagon; and an evaluation step of evaluating the cell population, based on the index calculated in the index calculation step.

Abstract: An object of the present invention is to provide a therapeutic agent for hereditary spastic paraplegia (HSP) SPG4. Specifically, the present invention relates to a composition for preventing or treating a neurodegenerative disease such as hereditary spastic paraplegia SPG4, the composition comprising, as an active ingredient, a substance that inhibits a function of miR-33a.

Abstract: The present invention provides markers for judging the efficacy of therapy with a PD-1 signal inhibitor before or at an early stage of the therapy. As biomarkers for predicting or judging the efficacy of therapy with a PD-1 signal inhibitor, surrogate indicators of metabolic changes relating to mitochondrial activity in T cells and/or T cell activation in a subject are used. As such indicators, intestinal flora-related metabolites in the serum or plasma, energy metabolism-related metabolites in the serum or plasma, amino acid metabolism-related metabolites and/or derivatives thereof in the serum of plasma, oxygen consumption rate and/or ATP turnover in peripheral blood CD8+ cells, amino acids in T cells, and T-bet in peripheral blood CD8+ cells may be used.

Abstract: The following are disclosed: a method for producing a T cell progenitor, including step (1) of culturing CD34+ cell in a medium containing an aryl hydrocarbon receptor antagonist, a medium for T cell progenitor differentiation containing an aryl hydrocarbon receptor antagonist, and a T cell progenitor inducer containing an aryl hydrocarbon receptor antagonist.

Abstract: A blockchain network system includes a plurality of sensor devices and a blockchain network. The sensor devices are communicably connected with each other via the blockchain network, and sensor data acquired by the sensor devices is managed on the blockchain network in a distributed manner The sensor device includes a sensor unit for sequentially acquiring sensor data in real space on a frame-by-frame basis, a data processing unit for processing the sensor data, a data storage unit for storing the sensor data, an encryption unit for encrypting the sensor data, and a registration unit for registering the sensor data encrypted by the encryption unit on the BC network. The data processing unit aggregates the sensor data with a predetermined number of frame aggregations. The encryption unit collectively encrypts the sensor data aggregated by the data processing unit with the predetermined number of frame aggregations.

Abstract: In a method for producing hydrogen and carboxylic acid, a primary alcohol of 1 to 7 carbon atoms and water are reacted by being continuously introduced into a flow reactor packed with a solid catalyst consisting of an alloy of ruthenium and tin on a support and passed through the reactor under temperature and pressure conditions at which the water assumes a gaseous state. This method enables hydrogen and carboxylic acid to be produced in a high yield or at a high purity from a primary alcohol and water in a short time and by simple operations.

Abstract: According to one embodiment, a structure evaluation system according to an embodiment includes a plurality of sensors, a position locator, and an evaluator. The plurality of sensors detect elastic waves. The position locator locates positions of elastic wave sources by using the elastic waves among the plurality of elastic waves respectively detected by the plurality of sensors having an amplitude exceeding a threshold value determined according to positions of the sources of the plurality of elastic waves and the positions of the plurality of disposed sensors. The evaluator evaluates a deteriorated state of the structure on the basis of results of the position locating of the elastic wave sources which is performed by the position locator.

Abstract: A pharmaceutical composition for suppressing neuro-inflammation; a pharmaceutical composition for assisting transplantation of neuron precursor cells, pluripotent stem cells, and/or neurons; a pharmaceutical composition for promoting the stabilization of Nrf2 protein in glial cells; a pharmaceutical composition for protecting nerve cells from neuro-inflammation are provided. Provided is a pharmaceutical composition containing, as an active ingredient, a compound having an inhibiting ability against phosphorylation activity of DYRK1A protein, or a pharmaceutically acceptable salt of the compound.

Abstract: Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3+ T cells can be induced by treating Foxp3? T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.

Abstract: An optically pumped magnetometer 1 includes: a cell 2; a pump laser 7 that emits pump light; one or more pump light mirrors that cause the pump light guided in a first direction; a probe laser 8 that emits probe light; a splitting unit 12 that splits the probe light into multiple light components; one or more probe light mirrors that cause each of the probe light components guided in a second direction, which is a direction perpendicular to the first direction; a detection unit that detects each of the probe light components perpendicular to the pump light inside the cell 2; and a derivation unit that derives a magnetic field corresponding to a region where each of the probe light components and the pump light are perpendicular to each other based on a detection result of the detection unit.

Abstract: A pharmaceutical composition for treating cartilage dysplasia, comprising 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof, and a treatment method using the pharmaceutical composition.